Microdosing (Part 2): The placebo effect with Balázs Szigeti
Business Trip, a podcast about psychedelic entrepreneurship
Welcome back to Business Trip, a podcast about psychedelic entrepreneurship! 🍄
This is part 2 or our 3 part series on microdosing that explores the science, history, and clinical applications. In part 1, we interviewed psychedelic researcher James Fadiman about the fundamentals of microdosing.
In part 2, we wanted to understand the placebo effect. In particular, is it the microdose that makes people feel better or it is a placebo effect? We interviewed Balázs Szigeti, PhD, who is a researcher associate at the Centre for Psychedelic Research at Imperial College London. His team conducted the largest placebo-controlled microdosing study in 2020. Balázs unpacks the study and their findings in the episode.
In this episode, we discuss:
The results of the study and what it means about the efficacy of microdosing
The study’s design and the self-blinding methodology
How to design a study that is more likely to be approved by FDA
Listen to the episode here, on Spotify or Apple Podcasts.
Subscribe to our newsletter to receive next week’s microdose (aka Part 3 in the series).
About Us
Business Trip tells the story of the emerging industry of psychedelics. Each episode features a new company in the field, ranging from biotech startups developing novel compounds, to clinics and retreats for healing, to software companies building tools to power the ecosystem.
Business Trip is produced by Greg Kubin and Matias Serebrinsky — we’re partners at PsyMed Ventures, advocates of the healing powers of psychedelic medicine and see a bright future ahead for the industry.
Thanks for listening,
💖 Know someone who would enjoy Business Trip?